GRI Bio, Inc. (GRI) Stock

GRI Bio, Inc. (GRI) is a Healthcare stock trading at $1.67 (as of 2026-08-21), with a market capitalization of $3.65M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing and commercializing therapies for inflammatory, fibrotic, and autoimmune diseases in the United States. Its pipeline includes GRI-0621, an oral inhibitor of type 1 Natural Killer T cells in a Phase IIa trial for severe fibrotic lung disease, and other oral NK T cell–targeted candidates in clinical and preclinical development.

Valuation — source: SEC EDGAR (first-party)
Price$1.67
Market Cap$3.65M
Price / Book0.36
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGEODE CAPITAL MANAGEMENT, LLC ($42222.00)
Institutional Holders Tracked9
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOW. Marc Hertz
Employees3
CountryUS
IPO Date2023-04-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Revelation Biosciences, Inc. (REVB)
  • FibroBiologics, Inc. Common Stock (FBLG)
  • Genprex, Inc. (GNPX)
  • Artelo Biosciences, Inc. (ARTL)
  • 60 Degrees Pharmaceuticals, Inc. (SXTP)
  • Ernexa Therapeutics Inc. (ERNA)
  • Onconetix, Inc. (ONCO)
  • HCW Biologics Inc. (HCWB)
GRI earnings history · GRI institutional & insider holders · GRI KPIs & operating metrics · GRI financials · GRI investor presentations & press releases · GRI SEC filings · GRI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.